Retention in methadone and buprenorphine treatment among African Americans.

Jan Gryczynski, Shannon Gwin Mitchell, Jerome H Jaffe, Sharon M Kelly, C Patrick Myers, Kevin E O'Grady, Yngvild K Olsen, Robert P Schwartz

Index: J. Subst. Abuse Treat. 45(3) , 287-92, (2013)

Full Text: HTML

Abstract

Methadone has been the most commonly used pharmacotherapy for the treatment of opioid dependence in U.S. public sector treatment, but availability of buprenorphine as an alternative medication continues to increase. Drawing data from two community-based clinical trials that were conducted nearly contemporaneously, this study examined retention in methadone versus buprenorphine treatment over 6 months among urban African Americans receiving treatment in one of four publicly-funded programs (N=478; 178 methadone; 300 buprenorphine). Adjusting for confounds related to medication selection, survival analysis revealed that buprenorphine patients are at substantially higher risk of dropout compared to methadone patients (HR=2.43; p<.001). Buprenorphine's retention disadvantage appears to be concentrated in the earlier phases of treatment (approximately the first 50 days), after which risk of subsequent dropout becomes similar for the two medications. These findings confirm a retention disparity between methadone and buprenorphine in this population, and suggest potential avenues for future research to enhance retention in buprenorphine treatment.Copyright © 2013 Elsevier Inc. All rights reserved.